Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 1,133 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) COO Anish Patel sold 1,133 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $20.06, for a total value of $22,727.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Anish Patel also recently made the following trade(s):

  • On Tuesday, May 14th, Anish Patel sold 1,107 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $27,675.00.
  • On Thursday, May 9th, Anish Patel sold 260 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.06, for a total transaction of $6,515.60.
  • On Monday, May 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.72, for a total transaction of $110,760.00.
  • On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.03, for a total transaction of $438,025.00.
  • On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.60, for a total transaction of $90,675.00.

Enliven Therapeutics Stock Performance

ELVN opened at $22.58 on Tuesday. The company has a 50-day moving average of $20.94 and a 200-day moving average of $16.77. The company has a market capitalization of $1.06 billion, a P/E ratio of -11.70 and a beta of 1.11. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its holdings in shares of Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares during the period. Baker BROS. Advisors LP bought a new stake in shares of Enliven Therapeutics during the 1st quarter worth $2,020,000. Blackstone Inc. bought a new stake in shares of Enliven Therapeutics during the 1st quarter worth $443,000. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics in the 1st quarter valued at $167,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics in the 4th quarter valued at $66,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Mizuho initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

View Our Latest Research Report on ELVN

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Further Reading

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.